Innovation/Impact: Ultrasound imaging is used during eye plaque placement to verify adequate tumor coverage and abutment of the plaque on the sclera. Imaging post-placement is not standardly performed however plaque movement and plaque tilt are known to occur and can ultimately compromise efficacy of the treatment. Post-operative volumetric imaging would be a beneficial quality assurance to verify tumor coverage and the plaques' position with respect to the sclera (plaque tilt). Conventional diagnostic computed tomography, operated with a kilovoltage potential, results in unacceptable image artifacts due to the gold or gold-alloy material of the plaque. The purpose of this phantom study is to investigate the possibility of imaging eye plaque positioning using the megavoltage computed tomography (MVCT) system of the Tomotherapy radiation therapy machine. MVCT is not subject to artifacts from high-Z materials such as gold, because the photo-electric effect does not contribute to attenuation of megavoltage photon beams. Compared to conventional a-Si MVCT, the xenon gas detectors of the Tomotherapy MVCT have approximately 10-fold better quantum efficiency 1,2
. Postimplantation magnetic resonance imaging (MRI) is possible, however MRI has the potential to injure the patient by radiofrequency heating of the gold plaque, and is contra-indicated for some patients due to implanted medical devices or other metal objects. Furthermore, MVCT is less time-consuming than MRI and is less expensive and logistically easier to schedule for radiotherapy patients because it is performed intra-departmentally.
Background: Episcleral eye plaque radiotherapy has been the treatment of choice for melanomas of the eye since the Collaborative Ocular Melanoma Study (COMS) demonstrated that plaque therapy results in equivalent overall survival compared to surgical enucleation of the eyeball. Plaque radiotherapy can be a vision sparing treatment, particularly in patients with small tumors located away from the optic disk and foveola. Efficacy of plaque therapy depends on the placement of the plaque with respect to the tumor. If the plaque is not centered on the tumor, dose delivered to the tumor could differ from the prescription dose and could result in lower tumor control probability. If the tumor base extends laterally beyond the edge of the plaque, gross under-dosing of the tumor will occur, with local failure a probable result. At our institution, a plaque is sized to extend such that a margin of at least 3 mm beyond the tumor exists in any direction, and ultrasound guidance is used intra-operatively to verify proper plaque placement. However, anterior tumors are difficult to measure with ultrasound. Plaque placement is further complicated by the fact that tumors may grow even during the time between diagnosis and plaque implantation (< 4 weeks, and typically < 2 weeks, at our institution). In our clinic, a small fraction of plaques have appeared to be "tilted" with respect to correct placement on the sclera (i.e. the plaque rim is not everywhere seated on the sclera). In a published report from another institution 3 , plaque tilt was observed more frequently during the plaque removal procedure than during implantation, indicating that plaques may shift during the treatment time, which typically comprises 3-7 days. 
Materials and Methods

